The National Institute for Health and Care Excellence (NICE) has recommended against approving Leqembi (lecanemab) and Kisunla (donanemab) to treat mild cognitive impairment or mild dementia caused by Alzheimer’s, in its final draft guidance.
The National Institute for Health and Care Excellence (NICE) has recommended against approving Leqembi (lecanemab) and Kisunla (donanemab) to treat mild cognitive impairment or mild dementia caused by Alzheimer’s, in its final draft guidance.